{
    "clinical_study": {
        "@rank": "102443", 
        "arm_group": [
            {
                "arm_group_label": "Part 1: Ingenol mebutate gel", 
                "arm_group_type": "Other", 
                "description": "Open-label, dose escalation, 2 or 3 days treatment"
            }, 
            {
                "arm_group_label": "Part 2: Ingenol mebutate gel X dose for 3 days treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "X dose for 3 days treatment"
            }, 
            {
                "arm_group_label": "Part 2: Ingenol mebutate gel X dose for 2 days  treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "X dose for 2 days treatment"
            }, 
            {
                "arm_group_label": "Part 2: Ingenol mebutate gel Y dose for 3 days treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "Y dose for 3 days treatment"
            }, 
            {
                "arm_group_label": "Part 2: Ingenol mebutate gel Y dose for 2 days treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "Y dose for 2 days treatment"
            }, 
            {
                "arm_group_label": "Part 2: Placebo for 3 days treatment", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for 3 days treatment"
            }, 
            {
                "arm_group_label": "Part 2: Placebo for 2 days treatment", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for 2 days treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "To identify the Maximum Tolerated Dose levels of ingenol mebutate gel after once daily\n      treatment for 2 or 3 consecutive days and to evaluate efficacy of ingenol mebutate gel in\n      different doses after once daily treatment for 2 or 3 consecutive days compared to vehicle\n      gel"
        }, 
        "brief_title": "Safety and Efficacy of Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days in Subjects With Actinic Keratosis", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Actinic Keratosis", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must be competent to understand the nature of the trial and provide informed\n             consent\n\n          -  Part 1: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the\n             face Part 2: Subjects with 5 to 20 clinically typical, visible and discrete AKs on\n             either the face, the balding scalp (the balding part of the scalp should be at least\n             25 cm2) or a contiguous area of approximately  250 cm2 on the chest\n\n          -  Subject at least 18 years of age\n\n          -  Female subjects must be of either:\n\n               1. Non-childbearing potential, i.e. post-menopausal or have a confirmed clinical\n                  history of sterility (e.g. the subject is without a uterus) or,\n\n               2. Childbearing potential, provided there is a confirmed negative urine pregnancy\n                  test prior to trial treatment, to rule out pregnancy\n\n          -  Female subjects of childbearing potential1 must be willing to use effective\n             contraception at trial entry and until completion\n\n        Exclusion Criteria:\n\n          -  Location of the treatment area (full face, full balding scalp or chest)\n\n               -  within 5 cm of an incompletely healed wound,\n\n               -  within 10 cm of a suspected basal cell carcinoma (BCC) or squamous cell\n                  carcinoma (SCC\n\n          -  Prior treatment with ingenol mebutate gel within the treatment area\n\n          -  Lesions in the treatment areas that have:\n\n               -  atypical clinical appearance (e.g., hypertrophic, hyperkeratotic or cutaneous\n                  horns) and/or,\n\n               -  recalcitrant disease (e.g., did not respond to cryotherapy on two previous\n                  occasions\n\n          -  History or evidence of skin conditions other than the trial indication that would\n             interfere with the evaluation of the trial medication (e.g., eczema, unstable\n             psoriasis, xeroderma pigmentosum)\n\n          -  Use of cosmetic or therapeutic products and procedures which could interfere with the\n             assessments of the treatment areas.\n\n          -  Clinical diagnosis/history or evidence of any medical condition that would expose a\n             subject to an undue risk of a significant AE or interfere with assessments of safety\n             and efficacy during the course of the trial, as determined by the investigator's\n             clinical judgment\n\n          -  Any abnormal laboratory tests that are medically significant and would impact the\n             safety of the subjects or the interpretation of the trial results, as determined by\n             the investigator's judgment\n\n          -  Anticipated need for hospitalisation or out-patient surgery during the first 15 days\n             after the first trial medication application. Note that cosmetic/therapeutic\n             procedures are not excluded if they fall outside of the criteria detailed in\n             Prohibited Therapies or Medications\n\n          -  Known sensitivity or allergy to any of the ingredients in ingenol mebutate gel\n\n          -  Presence of acute sunburn within the treatment areas\n\n          -  Current enrolment or participation in an investigational clinical trial within 30\n             days of entry into this trial.\n\n          -  Subjects previously assigned to treatment in Part 1 or rand\n\n          -  Female subjects who are breastfeeding.\n\n          -  In the opinion of the investigator, the subject is unlikely to comply with the\n             Clinical Study Protocol (e.g. alcoholism, drug dependency or psychotic state)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "426", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01820260", 
            "org_study_id": "LP0105-1012"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part 1: Ingenol mebutate gel", 
                    "Part 2: Ingenol mebutate gel X dose for 3 days treatment", 
                    "Part 2: Ingenol mebutate gel X dose for 2 days  treatment", 
                    "Part 2: Ingenol mebutate gel Y dose for 3 days treatment", 
                    "Part 2: Ingenol mebutate gel Y dose for 2 days treatment"
                ], 
                "intervention_name": "Ingenol mebutate gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part 2: Placebo for 3 days treatment", 
                    "Part 2: Placebo for 2 days treatment"
                ], 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 22, 2013", 
        "location": {
            "contact": {
                "last_name": "C. William Hanke, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Carmel", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "46032"
                }, 
                "name": "Laser & Skin Surgery Center of Inidana"
            }, 
            "investigator": {
                "last_name": "C. William Hanke, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "7", 
        "official_title": "Safety and Efficacy of Escalating Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days When Used on Full Face, Full Balding Scalp or Approximately 250 cm2 on the Chest in Subjects With Actinic Keratosis", 
        "overall_contact": {
            "email": "birgitte.vestbjerg@leo-pharma.com", 
            "last_name": "Birgitte Vestbjerg", 
            "phone": "+45 44 94 58 88"
        }, 
        "overall_official": {
            "affiliation": "Laser & Skin Surgery Center of Indiana", 
            "last_name": "C. William Hanke, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Part 1: Dose Limiting Toxicity based on LSRs up to and including Day 8", 
                "safety_issue": "Yes", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Part 2: Complete clearance of AKs", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01820260"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Part 2: Reduction in AK count", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 8"
            }, 
            {
                "description": "Partial clearance of AKs at Week 8, defined as at least 75% reduction from baseline in the number of clinically visible AKs", 
                "measure": "Part 2: Partial clearance of AKs", 
                "safety_issue": "No", 
                "time_frame": "Week 8"
            }
        ], 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}